Tick-borne encephalitis natural history, complications and prognosis

Revision as of 15:12, 4 February 2016 by Ilan Dock (talk | contribs) (Created page with "__NOTOC__ {{CMG}} {{AE}} {{IMD}} {{Tick-borne encephalitis}} ==Overview== ==Natural history== *Two thirds of infected individuals are asymptomatic and will not display any...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ilan Dock, B.S.

Tick-borne encephalitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tick-borne encephalitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

MRI

CT

Other Diagnostic Studies

Treatment

Medical Therapy

Future or Investigational New Therapies

Prevention

Case Studies

Case #1

Tick-borne encephalitis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tick-borne encephalitis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tick-borne encephalitis natural history, complications and prognosis

CDC on Tick-borne encephalitis natural history, complications and prognosis

Tick-borne encephalitis natural history, complications and prognosis in the news

Blogs on Tick-borne encephalitis natural history, complications and prognosis

Directions to Hospitals Treating Tick-borne encephalitis

Risk calculators and risk factors for Tick-borne encephalitis natural history, complications and prognosis

Overview

Natural history

  • Two thirds of infected individuals are asymptomatic and will not display any clinical manifestations.
  • Incubation period will last an average of 8 days. However incubation periods have been shown to range from 4-28 days.
  • Characteristic biphasic course:
  1. Early phase:
    • Disease will begin with the onset of nonspecific febrile illness accompanied by a headache, myalgia, and fatigue.
    • The early phase of the biphasic course will commonly occur over the course of several days.
    • Following common symptoms of the early infection phase, patient may display an afebrile and relatively asymptomatic period.
    • Nearly two-thirds of patients have been reported to have recovered without any further illness, following the completion of the first phase.
  1. Late phase:
    • As the disease progresses the onset of a second phase may result in central nervous system involvement including aseptic meningitis, encephalitis, or myelitis.
    • Further findings within the progression of tick borne-encephilitis include meningeal signs, altered mental status, cognitive dysfunction, ataxia, rigidity, seizures, tremors, cranial nerve palsies, and limb paresis.

Complications

  • The majority of complications associated with tick-borne encephilitis are commonly developed during the second phase. Complication may include:
    • Aseptic meningitis
    • Encephalitis
    • Myelitis
    • Meningeal signs
    • Altered mental status
    • Cognitive dysfunction
    • Ataxia
    • Rigidity
    • Seizures
    • Tremors
    • Cranial nerve palsies
    • Limb paresis

Prognosis

  • The prognosis is usually good for two-thirds of individuals diagnosed with tick-borne encephilitis. These patient will remain asymptomatic for the duration of the infection.
  • More severe cases have been associated with ages about 50 years as well as young children. Though severity in young children is less often reported than in elderly populations.
  • Prognosis also depends on subtype. European subtypes are commonly associated with lesser to mild symptoms while Far Eastern subtypes are associated with more severe cases and a case fatality ratio of 20-40%.
  • In humans, the disease is lethal in approximately 1.2% of cases and leaves 15-20% of its survivors with permanent neurological damage.